Journal profile · Neurosciences
Neurotherapeutics
ISSN 1933-7213 · eISSN 1878-7479 · Springer International Publishing · UNITED STATES · Quarterly · Founded 2004
Neurotherapeutics: CAS Zone 2 · Medicine (2025 upgraded edition); impact factor 7.44; fully open access; APC about USD 3,900; median 93 days to acceptance (100 articles, last 24 months); 270 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Neurotherapeutics is published by Springer International Publishing and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Genetic Neurodegenerative Diseases, Neurological disorders and treatments and Neuroinflammation and Neurodegeneration Mechanisms, together about 22.8% of its articles. Its main subfields are Neurology. (generated from OpenAlex topic counts and CAS ranking data)
Official journal of the American Society for Experimental NeurotherapeuticsNeurotherapeutics® is the journal of the American Society for Experimental Neurotherapeutics (ASENT). Each issue provides critical reviews of an important topic relating to the treatment of neurological disorders written by international authorities.The Journal also publishes original research articles in translational neuroscience including descriptions of cutting edge therapies that cross disciplinary lines and represent important contributions to neurotherapeutics for medical practitioners and other researchers in the field.Neurotherapeutics® delivers a multidisciplinary perspective on the frontiers of translational neuroscience, provides perspectives on current research and practice, and covers social and ethical as well as scientific issues.
From the journal's Aims & Scope
Research area (LetPub): Neurosciences
Editor-in-chief M. Maral MouradianPublisher website
Editorial board by country: none in mainland China; most named United States 48, United Kingdom 4, Canada 4, Taiwan, China 2, Japan 1 (61 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Genetic Neurodegenerative DiseasesNeuroscience8.3%
- Neurological disorders and treatmentsMedicine7.6%
- Neuroinflammation and Neurodegeneration MechanismsNeuroscience6.9%
- Parkinson's Disease Mechanisms and TreatmentsMedicine6%
- Neuroscience and Neuropharmacology ResearchNeuroscience5.6%
- Alzheimer's disease research and treatmentsMedicine5.4%
- Multiple Sclerosis Research StudiesMedicine4.8%
- Mitochondrial Function and PathologyBiochemistry, Genetics and Molecular Biology4.2%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Pharmacology & Pharmacy | Zone 1 |
| Minor | Clinical Neurology | Zone 2 |
| Minor | Neurosciences | Zone 2 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Clinical Neurology | Zone 2 |
| Minor | Neurosciences | Zone 2 |
| Minor | Pharmacology & Pharmacy | Zone 1 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Clinical Neurology | Zone 2 |
| Minor | Neurosciences | Zone 2 |
| Minor | Pharmacology & Pharmacy | Zone 2 |
Top journal: noReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 7.44LetPub ·
- Impact factor (publisher)
- 7.4Publisher website ·
- CiteScore 2026-06
- 12.6LetPub ·
- CiteScore (publisher)
- 12.6Publisher website ·
- SJR 2026-06
- 2.38LetPub ·
- SNIP 2026-06
- 1.93LetPub ·
- h-index
- 100LetPub ·
- h-index
- 158OpenAlex ·
- i10-index
- 1,578OpenAlex ·
- 2-year mean citedness
- 5.5OpenAlex ·
- Self-citation rate
- 1.4%LetPub ·
- Share of gold OA articles
- 84.52%LetPub ·
Volume
- Articles per year
- 174LetPub ·
Articles by year OpenAlex count · 2,772 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 242 | 242 | 113 |
| 2025 | 270 | 270 | 1,279 |
| 2024 | 188 | 188 | 2,455 |
| 2023 | 137 | 136 | 2,889 |
| 2022 | 163 | 163 | 5,602 |
| 2021 | 190 | 190 | 6,549 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
93 daysMedian, submission to acceptance · P25–P75 70 days – 114 days
- Acceptance to online
- median 13 days (99 articles)
- Submission to online
- median 108 days
- Sample
- 100 articles with submission and acceptance dates (448 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 6–12 weeksLetPub ·
- Submission to first decision
- 2 daysPublisher website ·
- Submission to acceptance
- 91 daysPublisher website ·
- Submission to publication (journal-reported)
- about 27 weeksDOAJ ·
- Peer review
- Double anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 3,900 | Yes | CC BY, CC BY-NC-ND | |
| OpenAlex | USD 3,900 / EUR 3,560 / GBP 3,120 / JPY 460,120 | — | — | |
| Publisher website | USD 3,900 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare4 items from the author guidelines
- Abstract
- 150–250 words
- Reference style
- Vancouver
- Suggested reviewers
- Required, 4
- Graphical abstract
- Optional
Article types accepted4
- commentariesThese are invited opinion pieces about original articles published in Neurotherapeutics written by experts in their fields providing an analysis of the research…Length not stated
- current perspectivesCurrent Perspectives are invited articles about current hot topics in the neurotherapeutics field.Length not stated
- invited reviews for thematic special issuesThese special issues are published quarterly and include a series of invited review articles relating to a specific topical theme.Length not stated
- original articlesOriginal research articles may be submitted for consideration at any time and must be uploaded through the submission website (https://www.editorialmanager.com/…Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Open access, Peer review, Preprints
- AI use Generative AI and Figures, images and artwork
Please read our policy on the use of generative AI and AI-assisted tools in figures, images and artwork, which can be found in Elsevier’s GenAI Policies for Journals. This policy states:We do not permit the use of Generative AI or AI-assisted tools to create or alter images in submitted manuscripts.The only exception is if the use of AI or AI-assisted tools is part of the research design or method…
Source ↗Publisher website ·- Authorship Changes to authorship
Authors are expected to consider carefully the list and order of authors before submitting their manuscript and provide the definitive list of authors at the time of the original submission. Any addition, deletion or rearrangement of author names in the authorship list should be made only before the manuscript has been accepted and only if approved by the journal Editor. To request such a change, …
Source ↗Publisher website ·- Conflicts of interest Declaration of interest
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential competing interests include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. Authors must disclose any interests in two places:…
Source ↗Publisher website ·- Open access Open Access
Fully Open Access journal Model summary
Neurotherapeutics is a fully Open Access Journal. Please visit our Open Access Page for more information.
Source ↗Publisher website ·- Peer review Peer review
Single anonymized review process Model summary
This journal operates a single anonymized review process. All contributions will be initially assessed by the editor for suitability for the journal. Papers deemed suitable are then typically sent to a minimum of two independent expert reviewers to assess the scientific quality of the paper. The Editor is responsible for the final decision regarding acceptance or rejection of articles. The Editor'…
Source ↗Publisher website ·- Preprints Preprints
Preprints can be shared anywhere at any time Model summary
Please note that preprints can be shared anywhere at any time, in line with Elsevier's sharing policy. Sharing your preprints e.g. on a preprint server will not count as prior publication (see 'Multiple, redundant or concurrent publication' for more information).
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Springer International Publishing
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Quarterly
- Founded
- 2004
- ISSN
- 1933-7213
- Electronic ISSN
- 1878-7479
- Society / sponsor
- American Society for Experimental Neurotherapeutics
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗Publisher website
- Author guidelines ↗DOAJ
- Aims & Scope ↗DOAJ
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗DOAJ
- Editorial board ↗DOAJ
FAQ
Frequently asked questions about Neurotherapeutics
What CAS zone is Neurotherapeutics in?
In the 2025 upgraded edition of the CAS Journal Ranking, Neurotherapeutics is in Zone 2 of Medicine, and in Zone 1 of the minor category Pharmacology & Pharmacy / Clinical Neurology / Neurosciences. In the 2026 Xinrui edition it is in Zone 1 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Neurotherapeutics?
The latest impact factor listed by LetPub is 7.44; CiteScore 12.6, h-index 158.
How long does peer review take at Neurotherapeutics?
Based on the dates recorded on 100 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 93 days (interquartile range 70–114 days); authors report an average review time of 6–12 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Neurotherapeutics?
According to the journal's author guidelines: Abstract: 150–250 words; Reference style: Vancouver; Suggested reviewers: Required, 4; Graphical abstract: Optional. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Neurotherapeutics based?
Of the 61 board members whose country the journal's board page names, none are in mainland China; the countries named most often are United States (48), United Kingdom (4) and Canada (4). Counted from the institutions listed on the board page; for reference only.
Which databases index Neurotherapeutics?
According to LetPub and DOAJ records, Neurotherapeutics is indexed in SCIE, Scopus and DOAJ.
Is Neurotherapeutics open access, and what is the APC?
Neurotherapeutics is a fully open-access journal. APC about USD 3,900.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .